AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6498701 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine group (n=100)
Number of subjects: 169
Study 6498701 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=100)
Number of subjects: 169
Study 6498701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 169
Study 30763661 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy hyperfractionated radiation therapy (RT) given in twice-daily fractions of 1.5 Gy each
Number of subjects: 25
Study 30763661 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy hyperfractionated RT
Number of subjects: 25
Study 30095381 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM) 1 g
Number of subjects: 230
Study 30095381 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (AMP) 1 g
Number of subjects: 230
Study 26863323 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (FiO2 = 15.0%)
Number of subjects: 8
Study 26863323 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FiO2 = 20.9%)
Number of subjects: 8
Study 24977247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosci technique
Number of subjects: 15
Study 24977247 — intervention group
Group type: COMPARATOR
Intervention: Summers technique
Number of subjects: 15
Study 24977247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 15
Study 22183220 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine subintestinal submucosal graft augmentation
Number of subjects: 160
Study 22183220 — intervention group
Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 160
Study 21058598 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical fitness program for 12 weeks
Number of subjects: 50
Study 21058598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 17416085 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical contact during venipuncture
Number of subjects: 0
Study 17416085 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical contact)
Number of subjects: 0
Study 15811562 — intervention group
Group type: COMPARATOR
Intervention: Diet (D-group; n = 25)
Number of subjects: 77
Study 15811562 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise (DE-group; n = 30)
Number of subjects: 77
Study 15811562 — intervention group
Group type: COMPARATOR
Intervention: Control group (C-group; n = 22)
Number of subjects: 77
Study 12472197 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum type IV collagen levels measured by ELISA
Number of subjects: 36
Study 12472197 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hemoglobin A1c (HbA1c)
Number of subjects: 36
Study 12472197 — intervention group
Group type: EXPERIMENTAL
Intervention: Twenty-four hour urinary albumin excretion rates (UAER)
Number of subjects: 36
Study 9531874 — intervention group
Group type: EXPERIMENTAL
Intervention: IM triptorelin (3.75 mg)
Number of subjects: 40
Study 9531874 — intervention group
Group type: EXPERIMENTAL
Intervention: SC triptorelin (3.75 mg)
Number of subjects: 40
Study 7866809 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy with absolute ethanol (group 1, n = 19)
Number of subjects: 35
Study 7866809 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL; group 2, n = 16)
Number of subjects: 35
Study 7866809 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy and EVL
Number of subjects: 35
Study 2487529 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (IND) 2.5 mg
Number of subjects: 13
Study 2487529 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg (HCTZ + A)
Number of subjects: 13
Study 787788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 868
Study 787788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study 28810466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuidate programme
Number of subjects: 626
Study 28810466 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study 26989888 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg PEX168
Number of subjects: 3
Study 26989888 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg PEX168
Number of subjects: 3
Study 26989888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 26296497 — intervention group
Group type: EXPERIMENTAL
Intervention: A/H5N2 live attenuated influenza vaccine
Number of subjects: 40
Study 26296497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22917442 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond FL (OF), three‐step total‐etch
Number of subjects: 30
Study 22917442 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus (OS), two‐step total‐etch
Number of subjects: 30
Study 22917442 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond All‐In‐One (OA), one step self‐etch
Number of subjects: 30
Study 22917442 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 21702674 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence PF
Number of subjects: 100
Study 21702674 — intervention group
Group type: COMPARATOR
Intervention: Treswhite Supreme
Number of subjects: 100
Study 19929597 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (E/S) combination therapy
Number of subjects: 0
Study 19929597 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 0
Study 19929597 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin
Number of subjects: 0
Study 17016527 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized IOP treatment protocol (ranging from topical monotherapy to filtration surgery)
Number of subjects: 258
Study 17016527 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized IOP treatment protocol
Number of subjects: 258
Study 12633984 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA application for 3 hours
Number of subjects: 40
Study 12633984 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA application for 2 hours
Number of subjects: 40
Study 12633984 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA application for 4 hours
Number of subjects: 40
Study 12633984 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA application for 3 hours and 4 hours
Number of subjects: 40
Study 10701278 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees semi‐Fowler position
Number of subjects: 62
Study 10701278 — intervention group
Group type: EXPERIMENTAL
Intervention: prone position
Number of subjects: 62
Study 10701278 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees laterally inclined position
Number of subjects: 62
Study 10701278 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees side lying position
Number of subjects: 62
Study 10701278 — intervention group
Group type: COMPARATOR
Intervention: Tempur polyethylene‐urethane mattress
Number of subjects: 62
Study 9062507 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (0.15 U/kg)
Number of subjects: 12
Study 9062507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin (0.15 U/kg)
Number of subjects: 12
Study 9062507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin (0.1 U/kg)
Number of subjects: 12
Study 9062507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of Lispro and Regular insulins (0.15 U/kg)
Number of subjects: 12
Study 9062507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralente insulin (0.2 U/kg)
Number of subjects: 12
Study 1288510 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 0.2 mg i.v.
Number of subjects: 6
Study 1288510 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 0.5 mg i.v.
Number of subjects: 6
Study 1288510 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 1.0 mg i.v.
Number of subjects: 6
Study 1288510 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 1.5 mg i.v.
Number of subjects: 6
Study 1288510 — intervention group
Group type: COMPARATOR
Intervention: n-butylscopolamine bromide 20 mg i.v.
Number of subjects: 6
Study 1288510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2949686 — intervention group
Group type: EXPERIMENTAL
Intervention: EXS Dacron
Number of subjects: 90
Study 2949686 — intervention group
Group type: COMPARATOR
Intervention: Human umbilical vein grafts (HUV)
Number of subjects: 90
Study 30739935 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2 mg/kg
Number of subjects: 64
Study 30739935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg/kg with Clonidine 1 µg/kg
Number of subjects: 64
Study 29435955 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular manual therapy
Number of subjects: 20
Study 29435955 — intervention group
Group type: COMPARATOR
Intervention: Back massage therapy
Number of subjects: 20
Study 26760111 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT 0.25 SPT units
Number of subjects: 151
Study 26760111 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT 0.5 SPT units
Number of subjects: 151
Study 26760111 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT 1.0 SPT units
Number of subjects: 151
Study 26760111 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT 2.0 SPT units
Number of subjects: 151
Study 26760111 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT 4.0 SPT units
Number of subjects: 151
Study 26760111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 24382170 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CTG
Number of subjects: 50
Study 24382170 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 50
Study 21780981 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Choices Intervention (PCI)
Number of subjects: 347
Study 21780981 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 347
Study 20212197 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 microg dexamethasone DDS
Number of subjects: 171
Study 20212197 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 microg dexamethasone DDS
Number of subjects: 171
Study 20212197 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 171
Study 20212197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (both dosages)
Number of subjects: 171
Study 17713400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control by intensive insulin therapy
Number of subjects: 0
Study 16218925 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate solution
Number of subjects: 5
Study 16218925 — intervention group
Group type: COMPARATOR
Intervention: Flavoured water (placebo)
Number of subjects: 5
Study 11994594 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated patients
Number of subjects: 60
Study 11994594 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated patients
Number of subjects: 60
Study 10470753 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal prostaglandin E1
Number of subjects: 350
Study 10470753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 10470753 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal prostaglandin E1 (with at least 85% of full dose)
Number of subjects: 350
Study 8682090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmunoglobulin
Number of subjects: 0
Study 8682090 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 0
Study 8682090 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 0
Study 8682090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2090189 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cholecystectomy and operative cholangiogram (group A)
Number of subjects: 127
Study 2090189 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy without operative cholangiogram (group B)
Number of subjects: 127
Study 287554 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant high-dose methotrexate and aggressive resection of pulmonary metastases
Number of subjects: 39
Study 287554 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients
Number of subjects: 39
Study 30907987 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine 50 μg once daily
Number of subjects: 952
Study 30907987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 952
Study 28184996 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (MB TKA)
Number of subjects: 41
Study 28184996 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (FB TKA)
Number of subjects: 41
Study 26228425 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 21
Study 26228425 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 21
Study 23529786 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral tablet of bilastine
Number of subjects: 12
Study 23529786 — intervention group
Group type: COMPARATOR
Intervention: 10 mg intravenous formulation of bilastine
Number of subjects: 12
Study 20512334 — intervention group
Group type: EXPERIMENTAL
Intervention: FDR GEM plus PACL
Number of subjects: 42
Study 18987965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 40
Study 18987965 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 40
Study 16759924 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis patients (n=6)
Number of subjects: 21
Study 16759924 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis patients (n=15)
Number of subjects: 21
Study 16759924 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=5)
Number of subjects: 21
Study 16759924 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=15)
Number of subjects: 21
Study 14657226 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation radiation (RT)
Number of subjects: 251
Study 14657226 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CTh)
Number of subjects: 251
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 U anti-factor Xa certoparin once daily
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 U anti-factor Xa certoparin twice daily
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 U anti-factor Xa certoparin twice daily
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: 8000 U anti-factor Xa certoparin twice daily
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 2
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 3
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group 4
Number of subjects: 404
Study 11136909 — intervention group
Group type: EXPERIMENTAL
Intervention: During certoparin treatment
Number of subjects: 404
Study 9209644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent in situ hybridization (FISH)
Number of subjects: 25
Study 9209644 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse-transcriptase PCR (RT-PCR)
Number of subjects: 25
Study 9209644 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostaining for p80 protein
Number of subjects: 25
Study 9209644 — intervention group
Group type: COMPARATOR
Intervention: FISH
Number of subjects: 25
Study 7711463 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 10
Study 7711463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3312399 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene (60 mg daily)
Number of subjects: 42
Study 31088732 — intervention group
Group type: EXPERIMENTAL
Intervention: active cTBS + facilitating cues
Number of subjects: 107
Study 31088732 — intervention group
Group type: COMPARATOR
Intervention: sham cTBS + facilitating cues
Number of subjects: 107
Study 31088732 — intervention group
Group type: EXPERIMENTAL
Intervention: active cTBS + inhibiting cues
Number of subjects: 107
Study 31088732 — intervention group
Group type: COMPARATOR
Intervention: sham cTBS + inhibiting cues
Number of subjects: 107
Study 30044704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity therapy
Number of subjects: 0
Study 26553236 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure targets (130-149 mm Hg)
Number of subjects: 0
Study 26553236 — intervention group
Group type: COMPARATOR
Intervention: Lower systolic blood pressure targets (<130 mm Hg)
Number of subjects: 0
Study 26553236 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher diastolic blood pressure
Number of subjects: 0
Study 26553236 — intervention group
Group type: COMPARATOR
Intervention: Lower diastolic blood pressure
Number of subjects: 0
Study 24728212 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin plus 2 g calcium daily until delivery
Number of subjects: 49
Study 24728212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 22852799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (271 children)
Number of subjects: 271
Study 22852799 — intervention group
Group type: COMPARATOR
Intervention: Control group (272 children)
Number of subjects: 271
Study 22852799 — intervention group
Group type: COMPARATOR
Intervention: Shadow control group (estimated 394 children)
Number of subjects: 271
Study 20173085 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg every 12 hours for 10 days
Number of subjects: 12
Study 20173085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17658393 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg and Valsartan 320 mg
Number of subjects: 1797
Study 17658393 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1797
Study 17658393 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 1797
Study 17658393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1797
Study 15821705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril alone (n=53)
Number of subjects: 287
Study 15821705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + Amiodarone (n=53)
Number of subjects: 287
Study 15821705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + Metoprolol (n=32)
Number of subjects: 287
Study 15821705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + Bisoprolol (n=32)
Number of subjects: 287
Study 15821705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + Carvedilol (n=32)
Number of subjects: 287
Study 15821705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + Atenolol (n=32)
Number of subjects: 287
Study 15821705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + Amiodarone + Carvedilol (n=53)
Number of subjects: 287
Study 12825762 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children (energy intake)
Number of subjects: 440
Study 12825762 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children (energy expenditure)
Number of subjects: 440
Study 12825762 — intervention group
Group type: COMPARATOR
Intervention: Non-obese children (physical activity level)
Number of subjects: 440
Study 12825762 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children (energy balance)
Number of subjects: 440
Study 12825762 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy balance (risk factor)
Number of subjects: 440
Study 10088735 — intervention group
Group type: EXPERIMENTAL
Intervention: Phakic anterior chamber intraocular lenses implantation
Number of subjects: 166
Study 10088735 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal detachment repair
Number of subjects: 166
Study 7589032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg gestodene and 0.03 mg ethinylestradiol
Number of subjects: 20
Study 7589032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg levonorgestrel and 0.03 mg ethinylestradiol
Number of subjects: 20
Study 7589032 — intervention group
Group type: COMPARATOR
Intervention: Both contraceptive formulations
Number of subjects: 20
Study 7589032 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (1 month after last intake)
Number of subjects: 20
Study 7589032 — intervention group
Group type: COMPARATOR
Intervention: Both preparations
Number of subjects: 20
Study 7589032 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and ethinylestradiol
Number of subjects: 20
Study 2107743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 50 mg bid
Number of subjects: 8
Study 2107743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine 100 mg bid
Number of subjects: 8
Study 2107743 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg bid
Number of subjects: 8
Study 2107743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 293505 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized suppressive therapy trial
Number of subjects: 735
Study 293505 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid operations
Number of subjects: 735
Study 30239017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of morphologic changes (Lateral Cartilage Clarity, Medial Cartilage Clarity, Medial Cartilage Thickness, Medial Meniscus Protrusion, Osteophytes at medial femoral margin)
Number of subjects: 113
Study 30239017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation including age and sex
Number of subjects: 113
Study 29091238 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scholar approach enhanced by systems engineering
Number of subjects: 0